Hypoxia-inducible factors in OSCC

Cancer Letters

Volumn 313, Issue 1, 2011, Pages 1-8

  Pérez Sayáns, Mario ^a   Suárez Peñaranda, José Manuel ^b   Pilar, Gayoso Diz ^b,c   Barros Angueira, Francisco ^b   Gándara Rey, José Manuel ^d   García García, Abel ^a,d  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c Santiago University Clinical Hospital   (Spain)

^d NONE   (Spain)

Author keywords

HIF 1 ; HIF 2 ; Hypoxia; Hypoxia inducible factors; Oral squamous cell carcinoma

Indexed keywords

2 METHOXYESTRADIOL; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; BAFILOMYCIN; CARBONATE DEHYDRATASE; CELECOXIB; CISPLATIN; CYTOGLOBIN; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; IMATINIB; MICRORNA; NITRIC OXIDE; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DRUG TARGETING; HUMAN; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR VOLUME;

EID: 80054123830     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.017     Document Type: Review

References (81)

1. Perez-Sayans M., Somoza-Martin J.M., Barros-Angueira F., Reboiras-Lopez M.D., Gandara Rey J.M., Garcia-Garcia A. Genetic and molecular alterations associated with oral squamous cell cancer (review). Oncol. Rep. 2009, 22:1277-1282.
2. Perez-Sayans M., Somoza-Martin J.M., Barros-Angueira F., Diz P.G., Rey J.M., Garcia-Garcia A. Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases. Cancer Lett. 2010.
3. Moulder J.E., Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metast. Rev. 1987, 5:313-341.
4. Supuran C.T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 2008, 7:168-181.
5. Eltzschig H.K., Carmeliet P. Hypoxia and inflammation. N. Engl. J. Med. 2011, 364:656-665.
6. Zhang X.Y., Wang X., Sun S.Z., Song Y., Yang M.X., Qu X. Effect of hypoxia inducible factor-1 alpha on vascular endothelial growth factor expression in human tongue squamous carcinoma cells (Tca8113) under hypoxia. Zhonghua Kou Qiang Yi Xue Za Zhi 2007, 42:747-749.
7. Liang X., Yang D., Hu J., Hao X., Gao J., Mao Z. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res. 2008, 28:1659-1666.
8. Sasabe E., Yang Z., Ohno S., Yamamoto T. Reactive oxygen species produced by the knockdown of manganese-superoxide dismutase up-regulate hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma cells. Free Radic. Biol. Med. 2010, 48:1321-1329.
9. Brennan P.A., Mackenzie N., Quintero M. Hypoxia-inducible factor 1alpha in oral cancer. J. Oral Pathol. Med. 2005, 34:385-389.
10. Semenza G.L. HIF-1 and human disease: one highly involved factor. Genes Dev. 2000, 14:1983-1991.
11. Makino Y., Kanopka A., Wilson W.J., Tanaka H., Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J. Biol. Chem. 2002, 277:32405-32408.
12. Sutter C.H., Laughner E., Semenza G.L. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc. Natl. Acad. Sci. USA 2000, 97:4748-4753.
13. Semenza G.L., Rue E.A., Iyer N.V., Pang M.G., Kearns W.G. Assignment of the hypoxia-inducible factor 1alpha gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q. Genomics 1996, 34:437-439.
14. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 2001, 292:464-468.
15. Jaakkola P., Mole D.R., Tian Y.M., et al. Targeting of HIF-alpha to the von hippel-lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
16. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003, 9:677-684.
17. Semenza G.L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 1999, 15:551-578.
18. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
19. Gerald D., Berra E., Frapart Y.M., Chan D.A., Giaccia A.J., Mansuy D., Pouyssegur J., Yaniv M., Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004, 118:781-794.
20. Ryan H.E., Lo J., Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998, 17:3005-3015.
21. Burri P., Djonov V., Aebersold D.M., Lindel K., Studer U., Altermatt H.J., Mazzucchelli L., Greiner R.H., Gruber G. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56:494-501.
22. Schindl M., Schoppmann S.F., Samonigg H., et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 2002, 8:1831-1837.
23. Birner P., Schindl M., Obermair A., Breitenecker G., Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 2001, 7:1661-1668.
24. Sivridis E., Giatromanolaki A., Gatter K.C., Harris A.L., Koukourakis M.I., Tumor and Angiogenesis Research Group Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002, 95:1055-1063.
25. Chen W.T., Huang C.J., Wu M.T., Yang S.F., Su Y.C., Chai C.Y. Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. Jpn. J. Clin. Oncol. 2005, 35:207-213.
26. Beasley N.J., Leek R., Alam M., Turley H., Cox G.J., Gatter K., Millard P., Fuggle S., Harris A.L. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002, 62:2493-2497.
27. Sasabe E., Tatemoto Y., Li D., Yamamoto T., Osaki T. Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci. 2005, 96:394-402.
28. Majmundar A.J., Wong W.J., Simon M.C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 2010, 40:294-309.
29. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 2010, 16:5928-5935.
30. Koh M.Y., Spivak-Kroizman T.R., Powis G. HIF-1alpha and cancer therapy. Recent Results Cancer Res. 2010, 180:15-34.
31. Uehara M., Sano K., Ikeda H., Nonaka M., Asahina I. Hypoxia-inducible factor 1 alpha in oral squamous cell carcinoma and its relation to prognosis. Oral Oncol. 2009, 45:241-246.
32. Wu L.C., D'Amelio F., Fox R.A., Polyakov I., Daunton N.G. Light microscopic image analysis system to quantify immunoreactive terminal area opposed to nerve cells. J. Neurosci. Methods 1997, 74:89-96.
33. Roh J.L., Cho K.J., Kwon G.Y., Ryu C.H., Chang H.W., Choi S.H., Nam S.Y., Kim S.Y. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol. 2009, 45:63-68.
34. Liang X., Zheng M., Jiang J., Zhu G., Yang J., Tang Y. Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma. Oral Oncol. 2011, 47:92-97.
35. Lin P.Y., Yu C.H., Wang J.T., Chen H.H., Cheng S.J., Kuo M.Y., Chiang C.P. Expression of hypoxia-inducible factor-1 alpha is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. J. Oral Pathol. Med. 2008, 37:18-25.
36. Costa A., Coradini D., Carrassi A., Erdas R., Sardella A., Daidone M.G. Re: levels of hypoxia-inducible factor-1alpha during breast carcinogenesis. J. Natl. Cancer Inst. 2001, 93:1175-1177.
37. Liu S.Y., Chang L.C., Pan L.F., Hung Y.J., Lee C.H., Shieh Y.S. Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma. Oral Oncol. 2008, 44:277-285.
38. Eckert A.W., Lautner M.H., Schutze A., Bolte K., Bache M., Kappler M., Schubert J., Taubert H., Bilkenroth U. Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J. Oral Pathol. Med. 2010, 39:313-317.
39. Eckert A.W., Lautner M.H., Schutze A., Taubert H., Schubert J., Bilkenroth U. Coexpression of hypoxia-inducible factor-1alpha and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology 2011.
40. Lee S.S., Tsai C.H., Yang S.F., Ho Y.C., Chang Y.C. Hypoxia inducible factor-1alpha expression in areca quid chewing-associated oral squamous cell carcinomas. Oral Dis. 2010, 16:696-701.
41. Tilakaratne W.M., Nissanka-Jayasuriya E.H. Value of HIF-1alpha as an independent prognostic indicator in oral squamous cell carcinoma. Exp. Rev. Mol. Diagn. 2011, 11:145-147.
42. Eckert A.W., Schutze A., Lautner M.H., Taubert H., Schubert J., Bilkenroth U. HIF-1alpha is a prognostic marker in oral squamous cell carcinomas. Int. J. Biol. Mark. 2010, 25:87-92.
43. Kyzas P.A., Stefanou D., Batistatou A., Agnantis N.J. Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study. Cancer Lett. 2005, 225:297-304.
44. Fillies T., Werkmeister R., van Diest P.J., Brandt B., Joos U., Buerger H. HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005, 5:84.
45. Percy M.J., Mooney S.M., McMullin M.F., Flores A., Lappin T.R., Lee F.S. A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair pro-564 hydroxylation. Mol. Cancer 2003, 2:31.
46. Prior S.J., Hagberg J.M., Phares D.A., Brown M.D., Fairfull L., Ferrell R.E., Roth S.M. Sequence variation in hypoxia-inducible factor 1alpha (HIF1A): association with maximal oxygen consumption. Physiol. Genom. 2003, 15:20-26.
47. Yamada N., Horikawa Y., Oda N., Iizuka K., Shihara N., Kishi S., Takeda J. Genetic variation in the hypoxia-inducible factor-1alpha gene is associated with type 2 diabetes in Japanese. J. Clin. Endocrinol. Metab. 2005, 90:5841-5847.
48. Hebert C., Norris K., Parashar P., Ord R.A., Nikitakis N.G., Sauk J.J. Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Mol. Cancer 2006, 5:3.
49. Roh J.L., Cho K.J., Kwon G.Y., Choi S.H., Nam S.Y., Kim S.Y. Prognostic values of pathologic findings and hypoxia markers in 21 patients with salivary duct carcinoma. J. Surg. Oncol. 2008, 97:596-600.
50. Griffiths E.A., Pritchard S.A., McGrath S.M., Valentine H.R., Price P.M., Welch I.M., West C.M. Hypoxia-associated markers in gastric carcinogenesis and HIF-2alpha in gastric and gastro-oesophageal cancer prognosis. Br. J. Cancer 2008, 98:965-973.
51. Yang Q.C., Zeng B.F., Dong Y., Shi Z.M., Jiang Z.M., Huang J. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn. J. Clin. Oncol. 2007, 37:127-134.
52. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., Semenza G.L. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001, 61:2911-2916.
53. Mohamed K.M., Le A., Duong H., Wu Y., Zhang Q., Messadi D.V. Correlation between VEGF and HIF-1alpha expression in human oral squamous cell carcinoma. Exp. Mol. Pathol. 2004, 76:143-152.
54. Hui E.P., Chan A.T., Pezzella F., et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res. 2002, 8:2595-2604.
55. Katsuta M., Miyashita M., Makino H., Nomura T., Shinji S., Yamashita K., Tajiri T., Kudo M., Ishiwata T., Naito Z. Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp. Mol. Pathol. 2005, 78:123-130.
56. Shaw R.J., Liloglou T., Rogers S.N., Brown J.S., Vaughan E.D., Lowe D., Field J.K., Risk J.M. Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br. J. Cancer 2006, 94:561-568.
57. Shaw R.J., Omar M.M., Rokadiya S., et al. Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer. Br. J. Cancer 2009, 101:139-144.
58. Hagen T., Taylor C.T., Lam F., Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003, 302:1975-1978.
59. Brune B., Zhou J., von Knethen A. Nitric oxide, oxidative stress, and apoptosis. Kidney Int. Suppl. 2003, (84):S22-4.
60. Tajima M., Kurashima Y., Sugiyama K., Ogura T., Sakagami H. The redox state of glutathione regulates the hypoxic induction of HIF-1. Eur. J. Pharmacol. 2009, 606:45-49.
61. Sun W., Zhou S., Chang S.S., McFate T., Verma A., Califano J.A. Mitochondrial mutations contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma. Clin. Cancer Res. 2009, 15:476-484.
62. Quintero M., Brennan P.A., Thomas G.J., Moncada S. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: role of free radical formation. Cancer Res. 2006, 66:770-774.
63. Brennan P.A., Quintero M. Hunterian lecture. Regulation of hypoxia-inducible factor 1 (HIF-1) by nitric oxide in oral squamous cell carcinoma. Ann. Roy. Coll. Surg. Engl. 2005, 87:153-158.
64. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
65. Dalmay T. MicroRNAs and cancer. J. Int. Med. 2008, 263:366-375.
66. Liu C.J., Tsai M.M., Hung P.S., Kao S.Y., Liu T.Y., Wu K.J., Chiou S.H., Lin S.C., Chang K.W. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010, 70:1635-1644.
67. Supuran C.T. Development of small molecule carbonic anhydrase IX inhibitors. BJU Int. 2008, 101(Suppl. 4):39-40.
68. Chang C.C., Lin B.R., Chen S.T., Hsieh T.H., Li Y.J., Kuo M.Y. HDAC2 promotes cell migration/invasion abilities through HIF-1alpha stabilization in human oral squamous cell carcinoma. J. Oral Pathol. Med. 2011.
69. Ishikawa T., Nakashiro K., Klosek S.K., Goda H., Hara S., Uchida D., Hamakawa H. Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol. Rep. 2009, 21:707-712.
70. Ryu M.H., Park H.M., Chung J., Lee C.H., Park H.R. Hypoxia-inducible factor-1alpha mediates oral squamous cell carcinoma invasion via upregulation of alpha5 integrin and fibronectin. Biochem. Biophys. Res. Commun. 2010, 393:11-15.
71. Unruh A., Ressel A., Mohamed H.G., Johnson R.S., Nadrowitz R., Richter E., Katschinski D.M., Wenger R.H. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003, 22:3213-3220.
72. Yoshiba S., Ito D., Nagumo T., Shirota T., Hatori M., Shintani S. Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest. Oral Oncol. 2009, 45:109-115.
73. Sasabe E., Zhou X., Li D., Oku N., Yamamoto T., Osaki T. The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int. J. Cancer 2007, 120:268-277.
74. Zhang Q., Zhang Z.F., Rao J.Y., Sato J.D., Brown J., Messadi D.V., Le A.D. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int. J. Cancer 2004, 111:849-857.
75. Perez-Sayans M., Reboiras-Lopez M.D., Somoza-Martin J.M., Barros-Angueira F., Gayoso Diz P., Gandara Rey J.M., Garcia-Garcia A. Measurement of ATP6V1C1 expression in brush cytology samples as a diagnostic and prognostic marker in oral squamous cell carcinoma. Cancer Biol. Ther. 2010, 9.
76. Perez-Sayans M., Garcia-Garcia A., Reboiras-Lopez M.D., Gandara-Vila P. Role of V-ATPases in solid tumors: importance of the subunit C (review). Int. J. Oncol. 2009, 34:1513-1520.
77. Perez-Sayans M., Somoza-Martin J.M., Barros-Angueira F., Rey J.M., Garcia-Garcia A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat. Rev. 2009, 35:707-713.
78. Lim J.H., Park J.W., Kim M.S., Park S.K., Johnson R.S., Chun Y.S. Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing hypoxia-inducible factor-1alpha. Mol. Pharmacol. 2006, 70:1856-1865.
79. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., Willard M.T., Zhong H., Simons J.W., Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3:363-375.
80. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 regulates a von hippel lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 2002, 277:29936-29944.
81. Okui T., Shimo T., Hassan N.M., Fukazawa T., Kurio N., Takaoka M., Naomoto Y., Sasaki A. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma. Anticancer Res. 2011, 31:1197-1204.